The USPTO has announced the COVID-19 Prioritized Examination Pilot Program to incentivize prompt research into treatment of this pandemic. The program will benefit small and micro entities by allowing them to file for prioritized examination without the typical fees. To qualify for this program, the claims of the application must cover a product or process that is subject to FDA approval for use in the prevention and/or treatment of COVID-19. The USPTO aims to reach final disposition of applications to this program within six months, if the applicant responds promptly to USPTO communications. WHIPgroup attorneys have significant experience in products and processes subject to FDA approval, including medical devices and chemical compositions. We are ready and able to help you take advantage of this program.
WHIPgroup successfully obtained an Order of Preliminary Injunction in connection with a Complaint and Emergency Motion for Temporary Restraining Order and Preliminary Injunction filed in the U.S. District Court for the Northern District of Georgia [Read More…]
WHIPgroup continues to represent its client’s best interests, filing counterclaims in an ongoing arbitration administered by the American Arbitration Association. WHIPgroup brought claims for breach of contract and unjust enrichment as well as tortious interference [Read More…]